Dysfibrinogenemia-Potential Impact of Genotype on Thrombosis or Bleeding.
Bor MV, Feddersen S, Pedersen IS, Sidelmann JJ, Kristensen SR.
Semin Thromb Hemost. 2022 Mar;48(2):161-173. doi: 10.1055/s-0041-1730358. Epub 2021 Jul 14.
Congenital dysfibrinogenemia in major surgery: A description of four cases and review of the literature.
Yan J, Luo M, Xiang L, Wu Y, Lin F.
Clin Chim Acta. 2022 Mar 1;528:1-5. doi: 10.1016/j.cca.2022.01.009. Epub 2022 Jan 19.
Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review.
Li Y, Ding B, Wang X, Ding Q.
Thromb Res. 2022 Sep;217:36-47. doi: 10.1016/j.thromres.2022.07.005. Epub 2022 Jul 14.
Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study.
de Lloyd L, Jenkins PV, Bell SF, Mutch NJ, Martins Pereira JF, Badenes PM, James D, Ridgeway A, Cohen L, Roberts T, Field V, Collis RE, Collins PW.
J Thromb Haemost. 2023 Apr;21(4):862-879. doi: 10.1016/j.jtha.2022.11.036. Epub 2022 Dec 22.
Diagnosis and management of dysfibrinogenemia.
Shapiro SE.
Clin Adv Hematol Oncol. 2018 Sep;16(9):602-605.
[Congenital dysfibrinogenemia: current status and challenges in diagnosis and treatment].
Wang Z, Zhu TN.
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):960-964. doi: 10.3760/cma.j.cn121090-20240326-00115.
Dysfibrinogenemia and thrombosis.
Hayes T.
Arch Pathol Lab Med. 2002 Nov;126(11):1387-90. doi: 10.5858/2002-126-1387-DAT.
Dysfibrinogenemia and thrombosis.
Mosesson MW.
Semin Thromb Hemost. 1999;25(3):311-9. doi: 10.1055/s-2007-994933.
Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management.
Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P.
J Thromb Haemost. 2015 Jun;13(6):909-19. doi: 10.1111/jth.12916. Epub 2015 May 2.
How I treat dysfibrinogenemia.
Casini A, de Moerloose P.
Blood. 2021 Nov 25;138(21):2021-2030. doi: 10.1182/blood.2020010116.
